Clinical Trial Update: The Value of 68Ga-grazytracer PET in Monitoring Responses to Immunotherapy of Advanced Soft Tissue Sarcomas

View source ↗

Summary

A clinical trial evaluating 68Ga-grazytracer PET for monitoring responses to immunotherapy in advanced soft tissue sarcoma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Soft Tissue Sarcoma

Snippet

Sponsor: Ruijin Hospital | Conditions: Advanced Soft Tissue Sarcomas | Status: RECRUITING